News | Structural Heart | January 06, 2021

FDA Grants Break Through Device Designation for TricValve Transcatheter Bicaval Valves System

Designation as Breakthrough Device by the U.S. Food and Drug Administration (FDA)

The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough device to P+F Products + Features GmbH TricValve Transcatheter Bicval Valves System. The system uses two self-expanding valves in the vena cava for the treatment of patients with hemodynamically relevant tricuspid insufficiency without the need to touch the native tricuspid valve. #TTVR

The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough device to P+F Products + Features GmbH TricValve Transcatheter Bicval Valves System. The system uses two self-expanding valves in the vena cava for the treatment of patients with hemodynamically relevant tricuspid insufficiency without the need to touch the native tricuspid valve.


January 6, 2021 — The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough device to P+F Products + Features GmbH TricValve Transcatheter Bicval Valves System.  

The FDA granted this status December 15, 2020. The TricValve is a system of two self-expanding biological valves for the treatment of patients with hemodynamically relevant tricuspid insufficiency and caval reflux. 

"The TricValve system represents a new technology offering a potentially simple, relatively low-risk yet effective treatment for patients with symptomatic severe tricuspid regurgitation (TR) and heart failure, many of whom harbor anatomy unfavorable for edge-to-edge repair or direct annuloplasty. It allows for all future options as patients stabilize and improve. We look forward to clinical trials in the US to further evaluate its safety and efficacy," said Samir Kapadia, M.D., chairman of the Department of Cardiovascular Medicine, and Rishi Puri, M.D., Ph.D., interventional cardiology, Cleveland Clinic.

The dedicated TricValve bioprostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve.

They are especially intended for use for patients at extreme risk or who are inoperable for open surgical therapy. The valves come fully pre-mounted thus facilitating the use of this innovative device in daily clinical practice.

"It is a huge milestone to receive the breakthrough device status for the TricValve. This could be a big change in the treatment of patients with severe TR made in Europe," said CEO of P+F, Katharina Kiss, M.D.

The TricValve is currently undergoing CE certification process. CE mark is expected in the first quarter of 2021.

P+F is developing a pipeline of transcatheter heart valves and grafts, as well as the Aortasave, a transcatheter endobentall solution for aortic dissection.

For more information: https://productsandfeatures.com

 

Find more transcatheter valve news and video

Related Content

News | Cath Lab

October 6, 2021 — Boston Scientific Corp. announced it entered into a definitive agreement to acquire Baylis Medical ...

Home October 06, 2021
Home
News | Cath Lab

September 21, 2021 — Medtronic is recalling its Pipeline Flex Embolization Device and Pipeline Flex Embolization Device ...

Home September 21, 2021
Home
Feature | Cath Lab | By Aaron Detate and Lars Thording

In the electrophysiology (EP) lab, hundreds of thousands of used devices are sent to reprocessors every year to get ...

Home September 14, 2021
Home
News | Cath Lab

July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of ...

Home July 22, 2021
Home
News | Cath Lab

July 13, 2021 — East End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company ...

Home July 14, 2021
Home
Feature | Cath Lab | By Dave Fornell, Editor

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal ...

Home May 14, 2021
Home
News | Cath Lab

May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has ...

Home May 12, 2021
Home
Feature | Cath Lab | By Dave Fornell, Editor

April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from the ...

Home May 06, 2021
Home
Videos | Cath Lab

Ashwin Nathan M.D., a cardiology fellow in the division of Cardiovascular Medicine at the Hospital of the University of ...

Home May 05, 2021
Home
News | Cath Lab

May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for stable ...

Home May 03, 2021
Home
Subscribe Now